Full Press Release Details
SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report first quarter 2018 financial results on Wednesday, May 9, 2018, after the NASDAQ market close.
The company will not be conducting a conference call in connection with this financial results press release.
About CytomX Therapeutics